BNP Paribas Financial Markets
EIDX

BNP Paribas Financial Markets’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

BNP Paribas Financial Markets’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,062
Closed -$271K – 4238
2020
Q4 		$271K Sell
2,062
-510
-20% -$45.1K ﹤0.01% 2742
2020
Q3 		$130K Buy
2,572
+2,153
+514% +$96.8K ﹤0.01% 2975
2020
Q2 		$20K Sell
419
-3,072
-88% -$143K ﹤0.01% 3397
2020
Q1 		$171K Buy
3,491
+2,170
+164% +$111K ﹤0.01% 2939
2019
Q4 		$75.8K Sell
1,321
-634
-32% -$31.4K ﹤0.01% 3427
2019
Q3 		$70.3K Buy
1,955
+114
+6% +$4.45K ﹤0.01% 3312
2019
Q2 		$57.2K Sell
1,841
-1,569
-46% -$42.5K ﹤0.01% 3340
2019
Q1 		$80K Buy
+3,410
New +$54.7K ﹤0.01% 3256

BNP Paribas Financial Markets's EIDX Position: Q1 2021 in Review

BNP Paribas Financial Markets sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 2,062 shares — an estimated $271K sold.

BNP Paribas Financial Markets first reported a position in EIDX in Q1 2019 and held it in 8 quarters. The position peaked at $271K in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • BNP Paribas Financial Markets reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 2,062 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $271K.
  • BNP Paribas Financial Markets first reported a position in Eidos Therapeutics, Inc. Common Stock in Q1 2019 and held it in 8 quarters.
  • BNP Paribas Financial Markets's Eidos Therapeutics, Inc. Common Stock position peaked at $271K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2021, filed 7 May 2021.